World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
110
Citations
59548
World Ranking
5451
National Ranking
2936

Overview

David P. Carbone is affiliated with The Ohio State University in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on Oncology and Pulmonary and Respiratory Medicine.

The scientist has contributed extensively to the study of cancer, with particular emphasis on lung cancer and cancer immunotherapy. Their work covers several subfields, including Molecular Biology, Cancer Research, and Immunology.

Key topics in David P. Carbone's research include:

  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Lung Cancer Diagnosis and Treatment
  • RNA modifications and cancer
  • Immunotherapy and Immune Responses

Frequent co-authors in their publications include:

  • Carolyn J. Presley
  • Dwight H. Owen
  • Peter G. Shields
  • Kai He
  • Gregory A. Otterson

The scientist's publications appear regularly in high-profile journals. Most frequent venues include:

  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Annals of Oncology

Some recent publications with their titles, years of publication, and associated venues are:

  • "First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial" (2021), The Lancet Oncology
  • "Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches" (2021), Annals of Oncology
  • "Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial" (2022), Nature Medicine
  • "Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results" (2022), Nature Medicine
  • "First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update" (2021), ESMO Open

Best Publications

  • Comprehensive genomic characterization of squamous cell lung cancers

    Peter S. Hammerman;Doug Voet;Michael S. Lawrence;Douglas Voet

  • Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.

    Dmitry I. Gabrilovich;Dmitry I. Gabrilovich;Hailei L. Chen;Khaled R. Girgis;H. Thomas Cunningham

  • First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    David P. Carbone;Martin Reck;Luis Paz-Ares;Benjamin Creelan

  • ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

    Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama

  • Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.

    Bond Almand;Joseph I. Clark;Ekaterina Nikitina;James van Beynen

  • Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo

    Dmitry Gabrilovich;Tadao Ishida;Tsunehiro Oyama;Sophia Ran

  • Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  • Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

    Li Yang;Laura M. DeBusk;Koari Fukuda;Barbara Fingleton

  • Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis

    Li Yang;Jianhua Huang;Xiubao Ren;Agnieszka E. Gorska

  • First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

    Luis Paz-Ares;Tudor-Eliade Ciuleanu;Manuel Cobo;Michael Schenker

  • Clinical Significance of Defective Dendritic Cell Differentiation in Cancer

    Bond Almand;John R. Resser;Brian Lindman;Sorena Nadaf

  • NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway

    Masaki Terabe;So Matsui;Nancy Noben-Trauth;Hangjiong Chen

  • Non-small-cell lung cancer

    Cesare Gridelli;Antonio Rossi;David P Carbone;Juliana Guarize

  • Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo: Presented in part at the Keystone Symposium “Cellular and Molecular Biology of Dendritic Cells,” Santa Fe, NM, March 3-9, 1998, and at the annual meeting of the American Association for Cancer Research, March 28-April 1, 1998.

    Dmitry Gabrilovich;Dmitry Gabrilovich;Tadao Ishida;Tadao Ishida;Tsunehiro Oyama;Tsunehiro Oyama;Sophia Ran;Sophia Ran

  • Proteomic patterns of tumour subsets in non-small-cell lung cancer.

    Kiyoshi Yanagisawa;Yu Shyr;Baogang J Xu;Pierre P Massion

  • Delivering affordable cancer care in high-income countries

    Richard Sullivan;Jeffrey Peppercorn;Karol Sikora;John Zalcberg

  • Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

    Roy S. Herbst;David H. Johnson;Eric Mininberg;David P. Carbone

  • Erratum: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells (Nature Medicine 2, 1096-1103 (1996))

    D. I. Gabrilovich;H. L. Chen;K. R. Girgis;H. T. Cunningham

  • Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells.

    Tsunehiro Oyama;Sophia Ran;Tadao Ishida;Sorena Nadaf

  • First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer

    David P. Carbone

Frequent Co-Authors

Pierre P. Massion
Pierre P. Massion Vanderbilt University Medical Center
Yu Shyr
Yu Shyr Vanderbilt University Medical Center
Gregory A. Otterson
Gregory A. Otterson The Ohio State University
Peter G. Shields
Peter G. Shields The Ohio State University
David H. Johnson
David H. Johnson The University of Texas Southwestern Medical Center
Hiroyuki Yamamoto
Hiroyuki Yamamoto St. Marianna University School of Medicine
Dmitry I. Gabrilovich
Dmitry I. Gabrilovich AstraZeneca (United Kingdom)
Kohzoh Imai
Kohzoh Imai University of Tokyo
John D. Minna
John D. Minna The University of Texas Southwestern Medical Center
Mark G. Kris
Mark G. Kris Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine, there are several flexible online degree options and alternative pathways that can help you get started or further your education, even if you are not ready to attend medical school in the USA.

Nursing degrees are popular and accessible choices. For current registered nurses hoping to advance their qualifications affordably, explore the rn to bsn cheapest programs available online. These programs let you earn a Bachelor of Science in Nursing (BSN) while maintaining your work schedule.

If you do not already have a nursing background, there are online bsn programs for non nurses that support career changers. Additionally, you can jumpstart your career in advanced practice nursing through direct entry msn programs for non nurses online, designed for students with bachelor’s degrees in other fields.

Another high-demand healthcare profession is medical billing and coding. Online programs from the best online medical billing and coding schools offer flexibility and financial aid, making them attractive for those seeking quick entry into the industry.

Best Scientists Citing David P. Carbone

Trending Scientists

Recently Published Articles